The A allele was associated with a significant, dose-dependent increase in the average MLH1 promoter methylation percentage of methylated reference (PMR) value in both dysplastic SSAs (PMR 48% in GG, 62% in GA genotype and 86% in AA genotype, ANOVA, p = 0.022,) and BRAF mutant cancers (PMR 14% in GG, 23% in GA and 36% in AA, ANOVA, p = 0.019, Fig. 2). This evidence concerns the gene MLH1 and cancer.